Anebulo Pharmaceuticals, Inc. (ANEB)

US — Healthcare Sector
Peers: TLSA  IMMX  WHWK  ZNTL  COYA  PLRX  CLNN  MGNX  ESLA  OKYO 

Automate Your Wheel Strategy on ANEB

With Tiblio's Option Bot, you can configure your own wheel strategy including ANEB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANEB
  • Rev/Share 0.0
  • Book/Share 0.237
  • PB 4.7468
  • Debt/Equity 0.0
  • CurrentRatio 17.3411
  • ROIC -0.8987

 

  • MktCap 46220322.0
  • FreeCF/Share -0.1444
  • PFCF -7.7907
  • PE -5.4749
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.6778

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
ANEB
Published: December 22, 2025 by: Business Wire
Sentiment: Neutral

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to “go private” in lieu of the previously announced reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500. Volunta.

Read More
image for news Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer

About Anebulo Pharmaceuticals, Inc. (ANEB)

  • IPO Date 2021-05-07
  • Website https://www.anebulo.com
  • Industry Biotechnology
  • CEO Richard Anthony Cunningham
  • Employees 2

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.